Clinical Trials Logo

Clinical Trial Summary

The goals of the proposed study are to evaluate the safety, tolerability and immunogenicity of a GBS vaccine. Previous studies suggest that immune responses against GBS can protect humans from infection.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Invasive Group B Streptococcus (GBS) Disease

NCT number NCT00657683
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 1
Start date December 2007
Completion date May 2009

See also
  Status Clinical Trial Phase
Completed NCT00645346 - A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age Phase 1